An experimental treatment for bone-thinning osteoporosis appears to prevent spine and hip fractures even though it is given only once a year, eliminating the need for a strict daily pill regimen, ...

Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Teva Pharmaceuticals announced FDA approval of a generic version of Forteo in the U.S. for certain women and men with osteoporosis, according to a company press release. The generic equivalent of ...

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos ...

UTC+8Zhangqiu District, Jinan City, Shandong Province – September 2025Uni-Bio Science Group (“the Group”) is pleased to announce the signing of a strategic cooperation agreement with Kexing Biopharm ...

Osteoporosis is the most common bone disease in the U.S., leading to increased risk of fractures and a weakening of bone strength and structure. Now, new guidelines on who should be tested could lead ...

While rare, premenopausal idiopathic osteoporosis is marked by low BMD and fragility fractures in younger women who don't ...

Researchers have combined injections of a novel hydrogel with systemic osteoporosis drugs in rats, achieving rapid local increases in bone density. The results offer hope for future fracture ...

Other treatments include hormone replacement therapy (estrogens), selective estrogen receptor modulators, calcitonin, and monoclonal antibodies. Denosumab, which binds to receptor activator of nuclear ...